Introduction
The vitamin D receptor (VDR) is a nuclear receptor, which acts as a transcriptional factor upon binding of the active form of vitamin D, 1a,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ] , and lithocholic acid. [1] [2] [3] Ligand-activated VDR forms a heterodimer with retinoid X receptor, binds to the vitamin D responsive-element and induces expression of its target genes, resulting in partial arrest in G0/G1 of the cell cycle, induction of diŠerentia-tion, or control of calcium homeostatis and maintenance of bone. In addition, VDR has been shown to be involved in induction of drug metabolizing enzymes CYP3A4, CYP2B6 and CYP2C9 in human primary hepatocytes, 2, 4) and CYP3A4 in intestinal cell lines. 2, 5) VDR and pregnane X receptor share 63z amino acid sequence identity in their DNA binding domains. 2) Like pregnane X receptor and constitutive androstane receptor, VDR transactivates CYP3A4 through binding to its distal DR3 and proximal ER6 elements. 4, 5) Recently, CYP3A4 has been shown to catalyze hydroxylation of 1,25(OH)2D3 in human liver and intestine, suggesting negative feedback control of 1,25(OH)2D3 action. 6) The VDR gene consists of 6 exon 1's (exons 1f, 1e, 1a, 1d, 1b, and 1c in this order) and 8 other exons (exons 2 to 9), and spans approximately 100 kb at chromosome 12q13.11.
7) The VDR protein is expressed in many tissues including kidney, skin and liver. 1) Alternative usage of exon 1's yields 14 transcripts including 3 major types: exon 1a-1c, exon 1d-1c or exon 1f-1c combinations, followed by common exons 2-9. 7) A translational initiation codon in exon 2 is used in transcripts starting from exon 1a or 1f. In the transcript from exon 1d (1d transcript), translation could initiate from the ATG codon in exon 1d, generating an active protein 50 amino acids longer than that from the exon 1a-or 1f-containing transcript (1a or 1f transcript). 7, 8) However, the 1d and 1f transcripts are assumed to be minor (expression levels were less than 10 and 20z, respectively, of the 1a transcript). 7) Genetic polymorphisms of transcriptional factors involved in induction of drug metabolizing enzymes could in‰uence their expression levels, and as a result drug pharmacokinetics/pharmacodynamics. As for VDR, several polymorphisms with functional signiˆcance have been reported. 9) For example, the single nucleotide polymorphism (SNP) 2TÀC (FokI polymorphism) in thê rst ATG codon of 1a and 1f transcripts results in generation of a three amino acid shorter protein, which has a signiˆcantly higher transcriptional activity than the longer transcript. 9, 10) Another SNP -29649GÀA upstream of exon 1e (thus exons 1a and 1d) is located in the Cdx2 (an intestinal transcriptional factor)-binding element. This nucleotide change facilitates Cdx2 binding, resulting in increased VDR transcription. 9, 11) Recently, Nejentsev et al. resequenced VDR and found 245 genetic variations in Caucasians (Britons). 12) However, no comprehensive screening of VDR polymorphisms has been reported for Asian populations including Japanese. In this study, we searched for VDR variations by resequencing the promoter regions, all 14 exons and their surrounding introns from 107 Japanese subjects.
Materials and Methods
Human genomic DNA samples: One hundred and seven Japanese cancer patients administered paclitaxel were analyzed. Written informed consent was obtained from all subjects. The ethical review boards of the National Cancer Center and the National Institute of Health Sciences approved this study. DNA was extracted from whole blood, which was collected from the patients prior to paclitaxel administration.
DNA sequencing Ampliˆcation of exon 1's, and exons 2 to 6: First, three sets of PCRs were separately performed to amplify exons 1f to 1b (Mix 1 primer set), the Cdx2 region (Mix 2), and exons 1c to 6 (Mix 3) from 50 ng of genomic DNA using 1.25 units of Z-Taq (Takara Bio Inc., Shiga, Japan) with 2 mM of each primer designed in the intronic regions ( Table 1 , 1st PCR). Theˆrst PCR conditions were 30 cycles of 989 C for 5 sec, 559 C for 5 sec, and 729 C for 190 sec. Next, exon 1's and exon 2 with high GC content were ampliˆed separately from the 1st PCR product as a template with 2.5 units of LA-Taq (Takara Bio Inc.) in GC buŠer I and 1 mM of each primer (2nd PCR in Table 1 ). For the Cdx2 region and exons 3 to 6, PCR reactions were performed using ExTaq (1 unit, Takara Bio Inc.) and 0.4 mM of primers in Table 1 . The second PCR conditions were 949 C for 5 min, followed by 30 cycles of 949 C for 30 sec, 609 C for 1 min, and 729 C for 2 min, and then aˆnal extension for 7 min at 729 C.
Ampliˆcation of exons 7 to 9: These exons were directly ampliˆed from 50 ng DNA. Ampliˆcation was performed with Ex-Taq for exons 7 to 8, 9-1 and 9-3, and with LA-Taq in GC buŠer I for exon 9-2. Primer concentrations, polymerase units and PCR conditions were the same as described above for the second round PCR.
Sequencing: PCR products were treated with a PCR Product Pre-Sequencing Kit (USB Co., Cleveland, OH, USA) and directly sequenced on both strands using an ABI BigDye Terminator Cycle Sequencing Kit ver. 3.1 (Applied Biosystems, Foster City, CA, USA) with sequencing primers listed in Table 1 (Sequencing). Excess dye was removed by a DyeEx96 kit (Qiagen, Hilden, Germany) and the eluates were analyzed on an ABI Prism 3730 DNA Analyzer (Applied Biosystems). All novel SNPs were veriˆed by sequencing PCR products obtained by a new genomic DNA ampliˆcation. Under the conditions used, up to 1,640 bases upstream of exon 1f, up to 4,090 (4,460) bases upstream of exon 1a (1d), all exons and their ‰anking introns were successfully sequenced for all subjects. VDR genomic sequence (NT_ 029419.11) and cDNA sequence (exon 1a-1c transcript, NM_000376.2) obtained from GenBank were used as reference sequences. Nucleotide positions based on cDNA sequence were numbered from the adenine of the translational start site (10416202 in NT_029419.11 and 161 in NM_000376.2) or the nearest exons (for introns 2 to 8).
Other analysis: Hardy-Weinberg equilibrium and linkage disequilibrium (LD) analyses were performed with SNPAlyze version 3.1 (Dynacom Co., Yokohama, Japan), and pairwise LDs between variations were obtained for rho square (r 2 ) values. P-values for HardyWeinberg equilibrium were corrected by false-discovery The position with an asterisk in parenthesis is numbered from the translational termination codon TGA. d The translational start site in exon 2 was used for numbering according to NM_000376.2. rate methods.
13)

Results and Discussion
We found 61 genetic variations, including 25 novel ones, from 107 Japanese subjects ( Table 2) . Of them, 9 were located in the 5?-‰anking region of exon 1f, 19 in the introns between the exon 1's, 2 in the 5?-untranslated region (UTR), 7 in the coding exons (5 synonymous and 2 nonsynonymous variations), 12 in the 3?-UTR, and 12 in introns 2 to 8. All observed allele frequencies were in Hardy-Weinberg equilibrium (pÀ0.05) after correction for multiple comparison, except for 3 linked variations -27671GÀA, -26593CÀT and -26385CÀT. Deviations from equilibrium were derived from an unexpected occurrence of one minor allele homozygote in these low frequency variations. However, the occurrence at these positions was conˆrmed by repeated sequencing.
One novel nonsynonymous variation, 154AÀG (Met52Val), was found heterozygously with an allele frequency of 0.005. The Met52Val is found in the nuclear localization signal between two zincˆnger regions. 14) Furthermore, the precedent amino acid Ser51 is phosphorylated by protein kinase C, which could modulate the VDR binding to the vitamin D responsiveelement and transactivation activity. 15) Thus, functional signiˆcance of this Met52Val variation should be claried in future studies. One known nonsynonymous SNP, 2TÀC (the FokI polymorphism) that results in increased transcriptional activity, was also detected at a 0.636 allele frequency, which is similar to frequencies reported for Japanese women (0.59) 10) and Caucasians (0.62), 16) but slightly higher than that in Chinese (0.53) 17) and lower than that in African-Americans (0.79). 16) Other functionally relevant SNPs are -29649GÀA and -26930AÀG. The SNP -29649GÀA, leading to higher a‹nity for Cdx2 and increased VDR transcription, was detected at a 0.430 frequency, which is higher and lower than those in Caucasians (0.17) and Africans (0.75), respectively. 18) By luciferase reporter and electrophoretic mobility shift assays, the other SNP -26930AÀG was shown to two-fold reduce VDR transcription with decreased binding a‹nity to a GATA protein.
18) The allele frequency of this variation was 0.028, which is comparable to that in Africans (0.06) but considerably lower than that in Caucasians (0.43). 18) Since GATA family proteins are expressed in many tissues, 19) this variation might be important for interindividual diŠerences in VDR expression levels. C-3387(*2103)_3406(*2122)A22-3427(*2143)A showed a 15z lower level and 30z faster decay of VDR mRNA than the minor reciprocal haplotype. 18) However, the variation responsible for these functional alterations has not been identiˆed. In our hands, the polymorphism 3387(*2103)_3406(*2122)A20ÀA13-24 could not be precisely genotyped by direct sequencing and thus is not listed in Table 2 . However, the four other SNPs were in very high LD (r 2 AE0.979) also in our Japanese population. Note that IVS8-49GÀT (known as the ApaI polymorphism) 9 ) also linked to these four variations (r 2 AE0.979). Thus, VDR mRNA stability is probably in‰uenced by this haplotype also in Japanese. The tagging SNP 1592(*308)CÀA (or IVS8-49GÀT) was detected at a 0.318 frequency, which is lower than that in Caucasians (0.55). 18) Moreover, it was shown that this SNP was also closely linked to IVS8＋283GÀA (the BsmI polymorphism). 18) In conclusion, we identiˆed 61 genetic variations, including 25 novel ones, from 107 Japanese subjects in VDR. One novel variation results in an amino acid substitution. Close associations of 5 SNPs [(IVS8-49GÀT, 1592 ( * 308) CÀA, 2077 ( * 793) delT, 3190 ( * 1906)CÀA, and 3427(*2143)AÀT] were also shown in Japanese. This information would be useful for pharmacogenetic studies to investigate the associations of VDR variations with interindividual diŠerences in drug metabolism catalyzed by VDR-regulated drug metabolizing enzymes in Japanese.
